Based on 14 analysts giving stock ratings to Rocket Pharmaceuticals Inc in the past month.
In the current month, RCKT has received 4 Buy Ratings, 6 Hold Ratings, and 2 Sell Ratings. RCKT average Analyst price target in the last month is 8.688.
Based on analysts' estimates, RCKT EPS is projected to reach -0.418 in FY2026Q4, following reported EPS of -0.433 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -0.43, while Rocket Pharmaceuticals IncRCKT's earnings per share (EPS) for the previous quarter was USD 1.09. EPS for the next quarter is expected at USD -0.42.